Rare Diseases Need Ongoing Natural History Studies To Speed Trials, FDA Says
CDER Director Janet Woodcock says rare disease advocates should consider organizing patients to study a rare disease history and progression.
You may also be interested in...
US FDA officials say they need knowledge of the disease to have the confidence to use accelerated approval.
Agency will make $2m available in 2017.
Straightforward draft document seems aimed at entities that have limited experience working with the agency.